Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101.

Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101. Leuk Lymphoma. 2013 Dec; 54(12):2654-9.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Alemtuzumab
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols
Consolidation Chemotherapy
Female
Humans
Immunoglobulin Heavy Chains
Leukemia, Lymphocytic, Chronic, B-Cell
Male
Middle Aged
Mutation
Neoplasm Staging
Remission Induction

authors with profiles

Richard A. Larson